PharmaTelevision - Hadasit Bio-Holdings Cultivates Good Science

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Hadasit Bio-Holdings Cultivates Good Science

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

With nine early stage companies in its portfolio at the start of 2009, Hadasit Bio-Holdings (HBL) may seem to some to be facing a tough year ahead.

Summary
Transcript
Participants
Company

With nine early stage companies in its portfolio at the start of 2009, Hadasit Bio-Holdings (HBL) may seem to some to be facing a tough year ahead. Ophir Shahaf, CEO, whilst recognising the challenge, has a plan in place and over the next 18 months hopes to take five or six through into clinical trials. Here he discusses the expected outcome of these young companies and how HBL intends to make sure they reach their full potential.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Ophir Shahaf
Managing Director
Hadasit Bio-Holdings Ltd

Ophir Shahaf was appointed to the position of Managing Director of Hadasit Bio-Holdings Ltd. - the publicly traded subsidiary of Hadasit, upon its IPO – in January 2006. He was promoted to the position of CEO in March, 2007. Mr. Shahaf is responsible for all of the ongoing activities of the public entity, including financial, legal, IR/PR, investment and fundraising issues.

Prior to this position, he served as VP business development at Protalix Biotherapeutics Ltd., a biopharmaceutical company focusing on the expression of human recombinant proteins in plant cell cultures. Adv. Shahaf was a part of the founding and management team of Clal Biotechnology Industries Ltd. – Israel's largest corporate investor in the life sciences, where he served as VP and general counsel, and participated in the management and investment of over $ 100 M.

Mr. Shahaf received his law degree from Tel Aviv University, and his MBA from the Stern School of Business at New York University, with a major in finance and international business. He teaches several courses in biotechnology entrepreneurship and management and is a fellow of the Merage Foundation at Irvine, CA.

Hadasit Bio-Holdings Ltd

Hadasit Bio-Holdings Ltd. was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST) in order to allow public participation in the highly promising field of biotechnology.

It serves as a precedent in biotech financing - for the first time, public investment is allowed to participate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").

In addition to the public holdings (33%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 9 biotech companies - all based on inventions developed and owned by HU.

Hadasit Bio-Holdings is a unique opportunity in the landscape of technology transfer offices & companies world-wide. It offers a fertile environment for the wedding of science, medicine, academia and business – within the framework of which a cluster of companies, focusing on a variety of therapeutic areas, will enjoy the benefits of a public offering. This framework serves to address an inherent problematic characteristic of investment in early-stage biotech by distributing both risk and the chance of success amongst a number of companies.